Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced the appointments of R. Clayton Fletcher as Senior Vice President, Business Development and Strategic Planning, and Jim Baker as Executive Director, Market Development. On Monday shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) closed at $4.67.
On 23 January, Oracle Corporation (NYSE:ORCL) said it has unveiled plans to open new offices in San Francisco and hire new top talent in order to develop next-generation platforms and infrastructure. On Monday shares of Oracle Corporation (NYSE:ORCL) closed at $43.90. Company’s sales growth for last 5 years was 10.50% and EPS growth for next 5 years is recorded as 8.50%.
Peoples Bancorp Inc. (NASDAQ:PEBO) reported fourth quarter and annual earnings results. Net earnings were $1.8 million or $0.32 basic and diluted net earnings per share for the three months ended December 31, 2014, as compared to $1.4 million or $0.25 basic and diluted net earnings per share, before adjustment for preferred stock dividends and accretion, for the same period one year ago. On last trading day Peoples Bancorp Inc. (NASDAQ:PEBO) increased 3.20% to close at $25.47. Its volatility for the week is 3.00% while volatility for the month is 3.27%. PEBO’s sales growth for past 5 years was -8.80% and its EPS growth for past 5 years was 18.00%. Peoples Bancorp Inc. (NASDAQ:PEBO) monthly performance is -2.41%.
Addus HomeCare Corporation (NASDAQ:ADUS) was downgraded byZacks from an “outperform” rating to a “neutral” rating in a report issued on Wednesday. They currently have a $26.10 target price on the stock. Zacks‘s price objective indicates a potential upside of 7.54% from the stock’s previous close. Addus HomeCare Corporation (NASDAQ:ADUS) has 0.20% insider ownership while its institutional ownership stands at 86.70%. In last trading activity company’s stock closed at $23.04.
On 22 January Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. On last trading day Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) moved up 4.43% to close at $6.37. Its volatility for the week is 5.47% while volatility for the month is 5.05%. ARIA’s sales growth for past 5 years was 45.10% and its EPS growth for past 5 years was -7.90%. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) monthly performance is -4.35%.